Catalyst Wire Dossier Catalyst Wire Dossier

CDR132L

· Novo Nordisk A/S
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for CDR132L, covering 2026-01-09 to 2026-08-26. Get the full timeline:

Most recent: Clinical Trial Results: Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction [Phase 2]

See pricing